Dr Bill Nelson speaks with Dr Drew Pardoll, the Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy, about the progress being made in empowering patient's own immune system to combat their cancer.
immunotherapy
Cancer Matters with Dr. Bill Nelson – Immunotherapy Before Surgery
Posted by | podcastDr Nelson talks with Dr Patrick Forde about his research showing the benefits of using immunotherapy treatments before surgery in lung cancer patients.
Immunotherapy for Lung Cancer
Posted by | precision medicine, treatmentIt’s lung cancer awareness month. Hear lung cancer expert Julie Brahmer and cancer genetics expert Victor Velculescu explain how immunotherapy is becoming a game changer for certain patients. Learn about the latest advances from our Bloomberg~Kimmel Institute for Cancer Immunotherapy and how we are helping patients with lung cancer live better and longer. Watch the(...)
Pancreatic Cancer Awareness Month
Posted by | Issues & Perspectives, treatmentIt’s Pancreatic Cancer Awareness Month, so we wanted to gather our best Kimmel Cancer Center resources for you. Learn more about cancer vaccines and other ways our experts are working to get the immune system to fight pancreatic cancer. Watch leading pancreatic cancer and immunology expert Elizabeth Jaffee, M.D., talk about new work from our(...)
‘Individualized’ Immune Cell Engineering Therapy for Cancer Clears First FDA Hurdle
Posted by | precision medicine*Update Aug. 30, 2017 - The FDA has approved the CAR-T therapy tisagenlecleucel for certain leukemia patients. News of an FDA advisory committee that has reviewed one pharmaceutical company's approach to engineering a cancer patient's own T-cells, the so-called soldiers of the immune system, and injecting them back into patients with astounding success has prompted questions(...)
Stefanie Joho describes how she participated in a landmark clinical trial of immunotherapy
Posted by | ResearchWhen doctors told Stefanie Joho that they had no options left, her sister scoured the internet to find "something" that could offer hope. She found a clinical trial at Johns Hopkins that looked promising, and little did Stefanie know that it would transform her life and become FDA approved. Listen to Stefanie tell her story:
Historic cancer drug approval has roots at Johns Hopkins and its Bloomberg~Kimmel Institute laboratories and clinics
Posted by | Issues & PerspectivesBreaking news today as, for the first time, a drug has been FDA-approved for cancer based on disease genetics rather than type. Developed from 30 years of basic research at Johns Hopkins and its Bloomberg~Kimmel Institute, pembroluzimab now can be used for colon, pancreatic, stomach, ovarian and other cancers if genetic testing reveals defects in(...)
Johns Hopkins Student Wins Top Prize For Research on Lethal Brain Tumors in Children
Posted by | Childhood Cancer, ResearchJohns Hopkins undergraduate student Sabrina Wang won first place in a competition among 125 students for her research on a lethal type of pediatric brain tumor called atypical teratoid/rhabdoid tumors (AT/RT), the most common brain tumor type in infants. The award was presented at the AACR 2017 annual meeting in Washington, D.C., on April 2.(...)
Training the next generation of cancer immunotherapy experts
Posted by | treatmentJiajia Zhang was a trained oncologist in China when she read news about former Vice President Joe Biden's visit to Johns Hopkins and the launch of the Bloomberg-Kimmel Institute. "I want to make more of an impact in patients' lives, and I believe immunotherapy is the future of cancer treatment," says Zhang. She decided to(...)
Making Real and Measureable Progress with Immunotherapy
Posted by | treatment--This blog post celebrates the one-year anniversary of the launch of the Bloomberg~Kimmel Institute for Cancer Immunotherapy. When we launched the Bloomberg~Kimmel Institute for Cancer Immunotherapy last March, we committed to accelerate the progress of immunotherapies in a real and measurable way, taking advantage of its ability to produce unprecedented and durable cancer regressions. We(...)